ClinicalTrials.gg
RecruitingNCT06759389VENTORUpdated Oct 22, 2026

The VENTOR Clinical Study

An interventional study of Resuscitation (Ventor) in Cardiac Arrest (CA), sponsored by CoLabs Medical. Recruiting at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by CoLabs Medical · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Oct 22, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.

Planned enrollment
85th of 117
25 · median 72
Started
2025
with 12 others
No phase
67 of 171
15 open now
Primary completion
2027-06
later than 14 of 44 live
Registered
151st of 171
by date

Among the 171 studies in Heart Arrest with a site in United States, this one is the 85th largest by planned enrollment of the 117 interventional ones that give a count, is one of 13 that started in 2025, is one of 67 with no phase, reaches primary completion later than 14 of the 44 other live ones, and was the 151st registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Heart Arrest with a site in United States, or all of them as a file.
02

Study summary

To evaluate the initial safety and effectiveness of the Ventor Airway System in providing short-term ventilation support in non-breathing subjects during cardiopulmonary resuscitation (CPR) and respiratory arrests.

03

Conditions studied

  • Cardiac Arrest (CA)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18-75 years, inclusive
  2. IHCA (non-traumatic)
  3. At least 4 feet in height

Exclusion criteria

Exclusion Criteria:

  1. Intubated with an endotracheal tube (ET)
  2. Valid do-not-attempt-resuscitation (DNAR) or study opt-out bracelet (including previous enrollment bracelet)
  3. LAR or Family member objects to enrollment
  4. Obvious signs of irreversible death (rigor mortis, dependent lividity, decapitation, transection, decomposition)
  5. Responsive with an intact gag reflex
  6. Blunt, penetrating, or burn-related injury, drowning, or electrocution
  7. Known upper airway foreign body or mass
  8. Lower airway obstruction
  9. Dental gap of \< 2 cm
  10. Ingested caustic substances
  11. Medicine Admitting Note's medical history is incomplete or has only been completed by an emergency physician.
  12. Known esophageal disease or facial/perforating neck trauma defined as study candidates with the following medical history:

    1. Diseases: (Esophageal Varices, Esophageal Cancer, Esophageal Strictures)
    2. Any patient on the following medications will be excluded: (Oxaliplatin, Leucovorin, Fluorouracil)
    3. Any patient with the following examination findings will be excluded: (Caput medusae, History or evidence of vomiting blood)
  13. Known vulnerable subject other Inclusion #3, such as known (e.g.: prisoner, pregnancy, terminal illness, dementia)
  14. History of medical, surgical or other conditions that, in the opinion of the investigator, would limit study participation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Ventor

    Subjects being treated with Ventor device

    Device: Resuscitation (Ventor)

Interventions

  • DeviceResuscitation (Ventor)

    Resuscitation with the Ventor device

06

What researchers measure

Primary outcomes

  1. Ability to provide oxygenation during CPR

    As measured through the monitoring of intra-arrest PaO2

    Time frame: From device insertion through 1 hour.

  2. Ability to provide ventilation during CPR

    As measured through the monitoring of intra-arrest PaCO2

    Time frame: From device insertion through 1 hour

  3. Ability to provide oxygenation during CPR

    As measured through the monitoring of intra-arrest cerebral oximetry

    Time frame: From device insertion through 1 hour

  4. Number of participants with device-related adverse events

    Number and rate of adverse events

    Time frame: From device insertion through 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jun 2027, 26 months after the start.

Of 219 interventional studies with no phase under Heart Arrest, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 26 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Jun 2026 → Jun 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Jan 6, 2025
StartActual
Apr 4, 2025
Primary completionEst.
Jun 2027was Jun 2026
CompletionEst.
Jun 2027was Jun 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Jun 2027
Oct 22, 2026
Study completion
Jun 2026→Jun 2027
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Primary completion Jun 2026→Jun 2027
    Study completion Jun 2026→Jun 2027
    + 3 other changes: verification date, oversight details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06759389
Lead sponsor
CoLabs Medical
Responsible party
Sponsor
First posted
Jan 6, 2025
Start date
Apr 4, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Clay Nolan
Contact
clayn@colabsmedical.com
(800) 592-6241
Jignesh Patel, M.D., M.Sc.
principal investigator · Stony Brook University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion